TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

Tenax Therapeutics investors saw the stock decline by roughly 84% to 85% in a single session after the Phase 3 LEVEL trial of TNX-103 failed to meet its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX shareholders.

NEW YORK--(BUSINESS WIRE)--A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

The magnitude of the decline reflects the importance of TNX-103 to Tenax’s business. The Company was pre-revenue, and TNX-103 was its lead clinical program. The LEVEL trial produced a 3.5-meter placebo-adjusted improvement in six-minute walk distance -- not statistically significant -- along with no meaningful difference from placebo on the Kansas City Cardiomyopathy Questionnaire symptom score. Topline data had been guided to August 2026, previously the third quarter of 2026.

Exploratory results disclosed alongside the topline data, including included stronger observed effects among patients with greater disease burden, but those findings did not alter the failed pivotal endpoints. The decline was company-specific: it followed clinical data, rather than an earnings shortfall or a revision to financial guidance. The investigation concerns whether investors were adequately informed of the risk concentrated in this single program.

Shareholders who lost money on TENX are encouraged to have their losses reviewed at no cost.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the TENX Investigation

Q: Who is eligible to participate in the TENX investigation? A: Investors who purchased TENX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did TENX stock drop? A: Shares fell approximately 84% to 85% after the Company disclosed that the Phase 3 LEVEL trial of TNX-103 missed its primary and key secondary endpoints. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Tenax Therapeutics made materially false or misleading statements regarding the status and prospects of its TNX-103 Phase 3 program. When the Company disclosed the failed LEVEL endpoints, the stock price declined sharply.

Q: What do TENX investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my TENX shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TENX and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if Tenax Therapeutics goes bankrupt before the matter resolves? A: Securities claims may survive bankruptcy in many circumstances. D&O insurance policies are frequently a potential source of recovery funds.

Attorney Advertising. Prior results do not guarantee similar outcomes.